Orna Therapeutics, Inc. has clinched its first big pharma partner for its novel circular RNA (oRNA) technology platform in a deal with Merck & Co., Inc., but the start-up is retaining its lead programs, in situ chimeric antigen receptor (CAR) therapies (isCARs).
Merck Buys Into Orna's Circular RNA Platform With Emphasis On Vaccines
Orna is retaining full ownership of its "crown jewel," in situ CAR programs for cancer. CEO Tom Barnes talked to Scrip about the deal and Orna's business strategy.
More from Deals
More from Business
• By
Chinese biopharma companies’ alliance strategies are transitioning from immediate cash needs to more strategic management of portfolios, as MNCs continue to hunt for derisked assets.
• By
As drugmakers update investors on first quarter financial performance, uncertainty around global trade and US regulatory oversight is likely to dominate discussions.
• By
Faced with Trump’s hostile tariff moves, the UK aims to speed up clinical trial start times to support its pharma sector and invest £600m in a new health data research service.